Cell Therapy News/Articles, page-12396

that article seems very bias against MSB, different story about a year ago with a splash about MSB getting ind\ustry award.
the article doesn't really give the full picture of what happened in the trials.....like the major aspect being our treatment was given after other treaments had already failed, those patients were end stage already before we got to them.
The endpiont etc of our trail was set a long time before it commenced and the pre treatment to patients had changed leading into the trials... so the data outcome were already flawed.
It was said if we were able to get in at an early stages of infection things would have been very different.
Other companies say the same about their products too... like Gilead saying there product no good in end stage patient. ..yet they get approved